nference develops an augmented intelligence software platform that makes unstructured, semi-structured, and structured biomedical information computable using state-of-the-art neural networks. The platform extracts insights from clinical notes, case reports, scientific literature, pathology images, ECG waveforms, and genomic sequences to support drug discovery, clinical research, and commercial operations. Founders Murali Aravamudan (CEO) and Venky Soundararajan (CSO) emphasize causal inference across differentiated biomedical knowledge at scale. nference positions its technology as the connective fabric across silos of health data and intends to expand applications across R&D and digital health. The company highlights patient-privacy considerations as central to its approach. nference is backed by Matrix Partners, Matrix Capital Management, Mayo Clinic Ventures, and NTT Venture Capital. The recent financing will be used to advance the platform for clinical research and therapeutic development. nference develops an artificial intelligence software platform that uses shallow and deep neural networks to extract and synthesize biomedical knowledge from scientific, regulatory and commercial literature. The platform is applied across R&D, commercial strategy and operations to enable hypothesis-free scientific research, target identification, patient stratification and lifecycle prioritization. The company emphasizes triangulating insights across structured databases and unstructured text to augment drug discovery and clinical development. nference plans to further develop its AI and R&D platforms, expand scientific operations in Cambridge, MA, and establish nference Labs in Bangalore, India. The team comprises serial tech entrepreneurs and Ph.D. scientists trained at MIT and Harvard Medical School, and the company has formed collaborations such as the Qrativ joint venture with the Mayo Clinic. nference also announced a world-class advisory board to support its scientific and clinical efforts.

Total raised

$71M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2020